AIM ImmunoTech CEO Thomas K. Equels reports acquiring $5,382 in shares

AIM•2026-11-12

AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 39,000 common shares at $0.138 per share, increasing his direct beneficial ownership to 293,095 shares.

AIM ImmunoTech CEO Thomas K. Equels reports acquiring $5,382 in shares

1. Share purchase

Related News

UK-US MeiraGTx Q3 net loss widens as R&D costs rise

Tiziana Life Sciences’ foralumab meets dual primary endpoints in Phase 2a MS trial

AMD to invest in PsiQuantum to advance quantum computing infrastructure

Sources

AIM ImmunoTech CEO Thomas K. Equels reports acquiring $5,382 in shares

Cohen & Company names Daniel G. Cohen CEO, succeeding Lester Brafman

Hancock Whitney agrees to acquire Trustmark for $3.2 billion